Genalyte appoints William A. Hagstrom to board of directors
Mr. Hagstrom is the founder and CEO of Octave Bioscience and the former CEO of Crescendo Bioscience.
Mr. Hagstrom brings extensive leadership experience with early and mid-stage biotechnology and diagnostics companies to Genalyte’s board.
Mr. Hagstrom previously served as president and CEO of Crescendo Bioscience, which concentrated on specialty diagnostics for autoimmune and inflammatory diseases, leading the company up to the acquisition of the company by Myriad Genetics in 2014.
Crescendo was recognized on the Inc. 500 list of fastest growing companies, the Deloitte Fast 500, Red Herring 100 and by Frost & Sullivan for Best in Class Diagnostics.
Prior to joining Crescendo, he was president of Alpha BioPartners, a strategic consulting firm specializing on early-stage biotechnology companies.
While at Alpha, he co-founded Biolytx Pharmaceuticals and Altheus Therapeutics. He also previously served as interim CEO of Selexys Pharmaceuticals and Inoveon.
Earlier, Mr. Hagstrom was Chairman and CEO of specialty diagnostics firm UroCor, as well as held executive positions at multinational healthcare firms Becton Dickinson, American Hospital Supply and Baxter International. ■
LATEST MOVES FROM California
- HP chairman Meg Whitman steps down
- Seagate Technology promotes Dave Mosley to CEO
- Autodesk appoints Reid French to board
- Plumas Bancorp appoints Richard F. Kenny to board
- PennyMac Financial Services appoints Theodore W. Tozer to board
More inside POST